TREATMENT OF IMATINIB RESISTANT LEUKEMIA USING 4-AMINOQUINOLINE-3-CARBONITRILES HAVING MUTATION IN THE BCRABL GENE

摘要

The present invention provides 4-anilino-3-quinolinecarbonitrile compounds useful for treating a subject having an BcrAbl positive leukemia that is resistant to imatinib. Such leukemias include those having a resistance-associated amino acid mutation in the bcrabl protein, e.g. F359V, H396P, I432T, F486S, M244V, L248V, G250E, Y253H, Y253F, E255K, K263E, L273M, T315I, F317L, and N331S.